Apolipoprotein B Synthesis Inhibition With Mipomersen in Heterozygous Familial Hypercholesterolemia | Zendy

Evan A. Stein | Zendy; Robert Dufour | Zendy; Claude Gagné | Zendy; Daniel Gaudet | Zendy; Cara East | Zendy; Joanne M. Donovan | Zendy; Wai Chin | Zendy; Diane L. Tribble | Zendy; Mary P. McGowan | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Apolipoprotein B Synthesis Inhibition With Mipomersen in Heterozygous Familial Hypercholesterolemia

Author(s) -

Evan A. Stein,

Robert Dufour,

Claude Gagné,

Daniel Gaudet,

Cara East,

Joanne M. Donovan,

Wai Chin,

Diane L. Tribble,

Mary P. McGowan

Publication year - 2012

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/circulationaha.112.104125

Subject(s) - medicine , familial hypercholesterolemia , apolipoprotein b , ldl cholesterol , endocrinology , cholesterol

Heterozygous familial hypercholesterolemia (HeFH) is a common genetic disorder leading to premature coronary artery disease. Despite statins and additional lipid-lowering therapies, many HeFH patients fail to achieve low-density lipoprotein cholesterol (LDL-C) goals. We evaluated mipomersen, an apolipoprotein B synthesis inhibitor, to further lower LDL-C in HeFH patients with coronary artery disease.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research